{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:03:09Z","timestamp":1788256989669,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"publisher","award":["OLL-890291"],"award-info":[{"award-number":["OLL-890291"]}],"id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-02021"],"award-info":[{"award-number":["2020-02021"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-04707"],"award-info":[{"award-number":["2020-04707"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010342","name":"Gillbergska Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"S\u00f6derbergs Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>To advance the understanding of inflammatory bowel disease [IBD] pathophysiology, we compared the mucosal and plasma metabolomes between new-onset paediatric IBD patients and symptomatic non-IBD controls, and correlated plasma inflammation markers and disease characteristics with the altered metabolites.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Paired colonic and ileal biopsies and plasma from 67 treatment-na\u00efve children with incident Crohn\u2019s disease [CD; n\u2005=\u200547], ulcerative colitis [UC; n\u2005=\u20059], and non-IBD controls [n\u2005=\u200511] were analysed using ultra-performance liquid chromatography-mass spectrometry [UPLC-MS\/MS]. Inflammatory plasma proteins [n\u2005=\u200592] were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The metabolomes in inflamed mucosal biopsies differed between IBD patients and controls. In CD, mucosal levels of several lysophospholipids [lysophosphatidylcholines, lysophosphatidyletanolamines, lysophosphatidylinositols, and lysophosphatidylserines] were decreased, correlating with various plasma metabolites including amino acid analogues and N-acetylated compounds. In both CD and UC, mucosal sphingolipids, including ceramide [d18:2\/24:1, d18:1\/24:2], lactosyl-N-palmitoyl-sphingosine [d18:1\/16:0], behenoyl sphingomyelin [d18:1\/22:0], lignoceroyl sphingomyelin [d18:1\/24:0], and\/or sphingomyelin [d18:1\/24:1, d18:2\/24:0] were increased, correlating with sphingolipids, bile acids, and\/or N-acetylated metabolites in plasma. Among proteins associated with CD, interleukin-24 correlated with plasma metabolites, including lactosyl-N-palmitoyl sphingosine [d18:1\/16:0] and phosphatidyletanolamine [18:1\/18:1], haemoglobin, and faecal calprotectin. In UC, interleukin-24, interleukin-17A, and C-C motif chemokine 11 correlated with several plasma metabolites, including N-acetyltryptophan, tryptophan, glycerate, and threonate, and with the Paediatric Ulcerative Colitis Activity Index, C-reactive protein, and faecal calprotectin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mucosal perturbations of lysophospholipids and sphingolipids characterised the metabolome in new-onset paediatric IBD and correlated with plasma metabolites. By integrating plasma metabolomics data with inflammatory proteins and clinical data, we identified clinical and inflammatory markers associated with metabolomic signatures for IBD.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac149","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T04:16:22Z","timestamp":1665202582000},"page":"418-432","source":"Crossref","is-referenced-by-count":31,"title":["Mucosal and Plasma Metabolomes in New-onset Paediatric Inflammatory Bowel Disease: Correlations with Disease Characteristics and Plasma Inflammation Protein Markers"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-8104","authenticated-orcid":false,"given":"Niklas","family":"Nystr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Prast-Nielsen","sequence":"additional","affiliation":[{"name":"Centre for Translational Microbiome Research, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Correia","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u2013 BMC, Science for Life Laboratory, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4526-5788","authenticated-orcid":false,"given":"Daniel","family":"Globisch","sequence":"additional","affiliation":[{"name":"Centre for Translational Microbiome Research, Karolinska Institutet , Stockholm , Sweden"},{"name":"Department of Chemistry \u2013 BMC, Science for Life Laboratory, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Engstrand","sequence":"additional","affiliation":[{"name":"Centre for Translational Microbiome Research, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Schuppe-Koistinen","sequence":"additional","affiliation":[{"name":"Centre for Translational Microbiome Research, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7234","authenticated-orcid":false,"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12876-017-0578-9","article-title":"Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study","volume":"17","author":"Ludvigsson","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/microorganisms10071371","article-title":"Gut microbiome in inflammatory bowel disease: role in pathogenesis, dietary modulation, and colitis-associated colon cancer","volume":"10","author":"Gubatan","year":"2022","journal-title":"Microorganisms"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Lloyd-Price","year":"2019","journal-title":"Nature"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1053\/j.gastro.2014.03.001","article-title":"The intestinal metabolome: an intersection between microbiota and host","volume":"146","author":"Ursell","year":"2014","journal-title":"Gastroenterology"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-019-0258-z","article-title":"Gut microbiota-derived metabolites as key actors in inflammatory bowel disease","volume":"17","author":"Lavelle","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/jcm10040622","article-title":"Metabolomics as a promising resource identifying potential biomarkers for inflammatory bowel disease","volume":"10","author":"Bauset","year":"2021","journal-title":"J Clin Med"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/proteomes8030018","article-title":"New insights into inflammatory bowel diseases from proteomic and lipidomic studies","volume":"8","author":"Longo","year":"2020","journal-title":"Proteomes"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/ecco-jcc\/jjaa227","article-title":"Metabolomic analysis in inflammatory bowel disease: a systematic review","volume":"15","author":"Gallagher","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ibd\/izy402","article-title":"Untargeted metabolomics and inflammatory markers profiling in children with Crohn\u2019s disease and ulcerative colitis: a preliminary study","volume":"25","author":"Daniluk","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"18879","DOI":"10.1038\/s41598-020-75306-z","article-title":"Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn\u2019s disease","volume":"10","author":"Diederen","year":"2020","journal-title":"Sci Rep"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/biom10071083","article-title":"Sphingolipid analysis indicates lactosylceramide as a potential biomarker of inflammatory bowel disease in children","volume":"10","author":"Filimoniuk","year":"2020","journal-title":"Biomolecules"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.advms.2019.12.009","article-title":"Metabolomic profiling in children with inflammatory bowel disease","volume":"65","author":"Filimoniuk","year":"2020","journal-title":"Adv Med Sci"},{"key":"2023040316012515900_","first-page":"321","article-title":"Faecal and serum metabolomics in paediatric inflammatory bowel disease","volume":"11","author":"Kolho","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/2472630320969147","article-title":"Metabolomic signatures in pediatric Crohn\u2019s disease patients with mild or quiescent disease treated with partial enteral nutrition: a feasibility study","volume":"26","author":"Marques","year":"2021","journal-title":"SLAS Technol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-017-1311-y","article-title":"Alterations in lipid, amino acid, and energy metabolism distinguish Crohn\u2019s disease from ulcerative colitis and control subjects by serum metabolomic profiling","volume":"14","author":"Scoville","year":"2018","journal-title":"Metabolomics"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.mri.2008.05.014","article-title":"Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study","volume":"27","author":"Balasubramanian","year":"2009","journal-title":"Magn Reson Imaging"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/metabo9120291","article-title":"Mucosal metabolomic profiling and pathway analysis reveal the metabolic signature of ulcerative colitis","volume":"9","author":"Diab","year":"2019","journal-title":"Metabolites"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"e76532","DOI":"10.1371\/journal.pone.0076532","article-title":"Altered colonic mucosal polyunsaturated fatty acid [pufa] derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiology","volume":"8","author":"Masoodi","year":"2013","journal-title":"PLoS One"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/jcm8070971","article-title":"The lipid status in patients with ulcerative colitis: sphingolipids are disease-dependent regulated","volume":"8","author":"Bazarganipour","year":"2019","journal-title":"J Clin Med"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn\u2019s disease activity index","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ibd.21452","article-title":"Short pediatric Crohn\u2019s disease activity index for quality improvement and observational research","volume":"17","author":"Kappelman","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/ibd.20867","article-title":"Appraisal of the pediatric ulcerative colitis activity index [PUCAI]","volume":"15","author":"Turner","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cgh.2012.08.003","article-title":"Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures","volume":"11","author":"Samuel","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"W388","DOI":"10.1093\/nar\/gkab382","article-title":"Metaboanalyst 5.0: narrowing the gap between raw spectra and functional insights","volume":"49","author":"Pang","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/bioinformatics\/bty1054","article-title":"Diablo: an integrative approach for identifying key molecular drivers from multi-omics assays","volume":"35","author":"Singh","year":"2019","journal-title":"Bioinformatics"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/biostatistics\/kxu001","article-title":"Variable selection for generalized canonical correlation analysis","volume":"15","author":"Tenenhaus","year":"2014","journal-title":"Biostatistics"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-0381-5-19","article-title":"Visualising associations between paired \u2018omics\u2019 data sets","volume":"5","author":"Gonz\u00e1lez","year":"2012","journal-title":"BioData Min"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2020.06.028","article-title":"Bioactive lipids, inflammation and chronic diseases","volume":"159","author":"Leuti","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"158854","DOI":"10.1016\/j.bbalip.2020.158854","article-title":"Bioactive lipids in inflammatory bowel diseases - from pathophysiological alterations to therapeutic opportunities","volume":"1866","author":"Alhouayek","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ibd.20993","article-title":"Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis","volume":"15","author":"Braun","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"e7197","DOI":"10.1371\/journal.pone.0007197","article-title":"Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression","volume":"4","author":"Bauer","year":"2009","journal-title":"PLoS One"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"102652","DOI":"10.1016\/j.ebiom.2020.102652","article-title":"A SNP of bacterial BLC disturbs gut lysophospholipid homeostasis and induces inflammation through epithelial barrier disruption","volume":"52","author":"Zou","year":"2020","journal-title":"EBioMedicine"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000064418","article-title":"Lisofylline and lysophospholipids ameliorate experimental colitis in rats","volume":"66","author":"Sturm","year":"2002","journal-title":"Digestion"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.plipres.2012.03.001","article-title":"Emerging roles for lysophosphatidylserine in resolution of inflammation","volume":"51","author":"Frasch","year":"2012","journal-title":"Prog Lipid Res"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4049\/jimmunol.1600264","article-title":"G2a signaling dampens colitic inflammation via production of IFN-\u03b3","volume":"197","author":"Frasch","year":"2016","journal-title":"J Immunol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.bbalip.2018.09.003","article-title":"Lysophosphatidylinositols in inflammation and macrophage activation: altered levels and anti-inflammatory effects","volume":"1863","author":"Masquelier","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.7150\/ijbs.67112","article-title":"Lipidomic trajectories characterize delayed mucosal wound healing in quiescent ulcerative colitis and identify potential novel therapeutic targets","volume":"18","author":"Bjerrum","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000200753","article-title":"Phospholipase a2 activity of colonic mucosa in patients with ulcerative colitis","volume":"50","author":"Almer","year":"1991","journal-title":"Digestion"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/gut.35.11.1593","article-title":"Increased group ii phospholipase a2 in colonic mucosa of patients with Crohn\u2019s disease and ulcerative colitis","volume":"35","author":"Minami","year":"1994","journal-title":"Gut"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","article-title":"Hmdb 5.0: the human metabolome database for 2022","volume":"50","author":"Wishart","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"eabf6584","DOI":"10.1126\/scisignal.abf6584","article-title":"Metabolomics activity screening of T cell-induced colitis reveals anti-inflammatory metabolites","volume":"14","author":"Montenegro-Burke","year":"2021","journal-title":"Sci Signal"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s10620-012-2127-2","article-title":"Serum metabolic profiling in inflammatory bowel disease","volume":"57","author":"Williams","year":"2012","journal-title":"Dig Dis Sci"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3748\/wjg.v20.i1.163","article-title":"Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases","volume":"20","author":"Dawiskiba","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40168-019-0689-3","article-title":"Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease","volume":"7","author":"Heinken","year":"2019","journal-title":"Microbiome"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid x receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J Lipid Res"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2017.08.028","article-title":"Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases","volume":"153","author":"Nikolaus","year":"2017","journal-title":"Gastroenterology"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"e0186142","DOI":"10.1371\/journal.pone.0186142","article-title":"Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles","volume":"12","author":"Andersson","year":"2017","journal-title":"PLoS One"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12967-021-02890-7","article-title":"Interleukin-24 regulates mucosal remodeling in inflammatory bowel diseases","volume":"19","author":"\u00d3nody","year":"2021","journal-title":"J Transl Med"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"964131","DOI":"10.1155\/2015\/964131","article-title":"Matrix metalloproteinases in inflammatory bowel disease: an update","volume":"2015","author":"O\u2019Sullivan","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2021.07.026","article-title":"Systemic inflammation in preclinical ulcerative colitis","volume":"161","author":"Bergemalm","year":"2021","journal-title":"Gastroenterology"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/pr300139q","article-title":"Quantitative metabolomic profiling of serum, plasma, and urine by [1]h nmr spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals","volume":"11","author":"Schicho","year":"2012","journal-title":"J Proteome Res"},{"key":"2023040316012515900_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12916-017-0949-7","article-title":"Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease","volume":"15","author":"Bjerrum","year":"2017","journal-title":"BMC Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac149\/47627891\/jjac149.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/3\/418\/49732330\/jjac149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/3\/418\/49732330\/jjac149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T16:34:48Z","timestamp":1701189288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/3\/418\/6758389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,10,11]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac149","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,10,11]]}}}